je.st
news
Tag: patients
RTP drug co. hears good news on drug to help pediatric cancer patients
2015-07-09 23:31:50| Logistics - Topix.net
Fennec Pharmaceuticals, Inc. reported positive safety data on an experimental drug that could prevent hearing loss in pediatric cancer patients. Based in Research Triangle Park, Fennec is developing a drug that would prevent hearing loss in patients who receive cisplatin, a common treatment that attacks cancers in children.
Patients' immediate needs dictate EMTs next move
2015-07-04 22:36:43| Biotech - Topix.net
Despite Newnan being dubbed a "medical mecca," there are times when people must be transported to Atlanta for more specialized and urgent care. The decision to ground transport a patient to Piedmont Newnan Hospital or to speciality hospitals, or to airlift the patient to trauma facilities in Atlanta, such as Atlanta Medical Center or Grady Memorial Hospital, is made by Coweta County emergency medical technicians who base their judgment on a four-step process.
Tags: next
move
patients
dictate
Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
2015-06-29 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Mercks substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). Language: English Contact: MerckMedia:Doris Li, 908-740-1903orAn Phan, 908-255-6325orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
How Gilead Sciences Is Gouging Hepatitis C Patients, $1,000 a Pill
2015-06-21 20:06:31| Biotech - Topix.net
A new wave of hepatitis C drugs is all the rage. But while these new pills boast cure rates of 90 percent in less time than their predecessors, their prices are causing rage.
Tags: sciences
patients
pill
hepatitis
Liver patients given a shot at life
2015-06-21 03:26:36| Biotech - Topix.net
Greg Jefferys, of Woodbridge, has Hepatitis C and has travelled to India to obtain drugs he needs for treatment which are highly expensive in Australia. Picture NIKKI DAVIS-JONES IT'S the breakthrough drug that thousands of Australians with liver disease have been praying for, but at more than $90,000, the treatment is cruelly beyond reach for all but a wealthy few.
Tags: life
shot
patients
liver
Sites : [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] next »